ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Nov 29, 2021||ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study|
|Nov 16, 2021||ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property with Issuance of 22nd and 23rd U.S. Patents|
|Nov 15, 2021||ENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update|
|Nov 08, 2021||ENDRA Life Sciences to Report Third Quarter 2021 Financial Results on November 15, 2021|
|Oct 13, 2021||ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property Protection with Issuance of 21st U.S. Patent|
|Day Range||0.9300 - 0.9800|
|52 Week Range||0.7030 - 3.1000|
|Bid/Ask||0.9600 / 0.9760|
|Bid/Ask Size||1,400 X 1,300|
|Market Cap||40.18 million|
|Shares Outstanding||41.86 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|